Johnson & Johnson Nordic AB Acquires Amic
Gains Access to In Vitro Diagnostic Technologies in Development for Use in Point-of-Care Settings
As a result of the acquisition, Johnson & Johnson expects to incur an estimated one-time after-tax charge of approximately $40 million during the second quarter of 2008 related to the expensing of in-process research and development. Other terms of the transaction were not disclosed.
Amic is developing technology that uses a chip-based micro-fluidic platform to enable fully quantitative, immunoassay tests in POC or near-patient settings. This next-generation technology represents an advance in an area of diagnostics where double-digit market growth is anticipated.
"This acquisition is a strategic opportunity to develop a Point-of-Care channel," said Mark Straley, Worldwide Commercial President, Ortho-Clinical Diagnostics, Inc. "We're committed to bringing novel assays and existing tests closer to the patient and delivering information to health care professionals when and where they need it."
Organizations
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.